Four Key Components of Our Corporate Strategy

Progress of the Four Key Components

“Our aspiration is to become a globally-leading medtech company contributing to people’s lives by delivering innovative solutions that benefit patients, healthcare professionals, payors and providers.” This is Olympus’ strategic aspiration under the corporate strategy, which aims to achieve an operating margin of over 20% for the fiscal year 2023. To achieve this target, we are promoting various initiatives.



A

- Focus the corporate portfolio, centering on the Medical Business

B

- Maintain leadership in reusable endoscopes
- Complement our portfolio with single-use endoscopes to accelerate growth and address unmet needs
- Evolve the endoscopy commercial model
  —shift towards service-based offerings and procedure-based business models

C

- Focus and scale prioritized therapeutic areas
  (GI-Endotherapy, Urology and Respiratory)

D

- Develop a leading position in next-generation minimally invasive surgery by delivering integrated technologies designed to improve clinical and economic outcomes

A Focus Our Corporate Portfolio

- Conducted multiple M&A to drive growth in the Medical Business
  (GI endoscopy: Arc Medical Design Ltd.; Respiratory: Veran Medical Technologies, Inc.; Orthopedic: FH ORTHO SAS; Surgical: Quest Photonic Devices B.V.)
- Exercised the call option and completed the acquisition of all outstanding shares of Medi-Tate Ltd.
- Completed the transfer of Olympus Systems Corporation, which offers IT solutions, to Accenture Japan Ltd.
- Completed the transfer of Olympus RMS Corporation, which specializes in manufacturing and development of regenerative medicines, to Rohto Pharmaceutical Co., Ltd.

B Further Strengthen Leadership in Endoscopy

Revenue Growth CAGR (FY2021 to FY2023) ~6%

- Continuing to expand sales of EVIS X1 through launch execution in current markets and preparation of launch into new markets
- Launch of ENDO-AID, AI-powered platform for the endoscopy system in EMEA and Asia Pacific
- Surgical endoscope system VISERA ELITE II launch in the United States and Chinese markets (United States: 3D and infrared (IR), China: 3D)

C Focus and Scale Our TSD Business

Revenue Growth CAGR (FY2021 to FY2023) ~8%

- In April 2021, opened a new facility in Westborough, Massachusetts, U.S., to consolidate the global headquarters of the Therapeutic Solutions Division and the sales and marketing functions of the U.S. Medical Business
- Establish a highly capable regulatory, medical and clinical affairs organization to develop strategies and portfolios
- Accelerating the discovery and vetting of future M&A targets mainly in the Therapeutics Solutions Division through increased early-stage investment activity
- In order to expand our product portfolio in three focus areas and to further strengthen core competencies in early diagnosis and minimally invasive treatments, we acquired the following companies for the Group: Arc Medical Design (GI-Endotherapy), which has products that contribute to maintaining visibility during colonoscopy and endoscopic polypectomies; Veran Medical Technologies (Respiratory), which has an advanced electromagnetic navigation system that assists in the insertion of bronchoscopes into the peripheral part of the lungs; and Medi-Tate (Urology), which has a minimally invasive therapeutic device for benign prostatic hyperplasia (BPH)

D Lead in Next-Generation Minimally Invasive Surgery

- Acquired Quest Photonic Devices B.V. including innovative technologies in the area of molecular and multi-spectral imaging, aiming to assist surgeons in performing safer procedures with better long-term outcome for the patient
- Research and development of endoluminal manipulator that allow less invasive therapies, inserting through a lumen such as mouth and anus